Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sorich

Showing results (71-80 of 216) with videos related to

Pageof 22
Sort By:
Journal of Cancer Research and Clinical Oncology|May 26, 2020
The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenibWarit Ruanglertboon, Michael J Sorich, Jessica M Logan, et al.
Journal of Clinical Pharmacology|November 27, 2024
Ritonavir May Prolong Sedation but is Unlikely to Increase the Risk of Respiratory Arrest in Patients Requiring Intravenous Midazolam for Procedural SedationJason Arsanious, Angela Rowland, Michael J Sorich, et al.
Cancers|October 18, 2018
Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical TrialsAshley M Hopkins, Anh-Minh Nguyen, Christos S Karapetis, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2010
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial dataM J Sorich, A Vitry, M B Ward, et al.
Pharmaceutical Research|February 26, 2017
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Mafalda M Dias, Michael J Sorich, Andrew Rowland, et al.
Journal of Oncology|July 5, 2021
Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse EventsJessica M Logan, Doug A Brooks, Andrew Rowland, et al.
International Journal of Cancer|June 4, 2020
Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapyAshley M Hopkins, Jordan Wagner, Ganessan Kichenadasse, et al.
European Journal of Clinical Pharmacology|March 25, 2018
Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestriesMadelé van Dyk, Jean-Claude Marshall, Michael J Sorich, et al.
American Journal of Pharmaceutical Education|February 9, 2011
Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy educationDavid M Plevin, Helena M Ward, Michael B Ward, et al.
Biomedicines|January 21, 2022
Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver DiseaseLauren A Newman, Zivile Useckaite, Jillian Johnson, et al.
Pageof 22

Showing results (71-80 of 216) with videos related to

Sort By:
Pageof 22
Journal of Cancer Research and Clinical Oncology|May 26, 2020
The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenibWarit Ruanglertboon, Michael J Sorich, Jessica M Logan, et al.
Journal of Clinical Pharmacology|November 27, 2024
Ritonavir May Prolong Sedation but is Unlikely to Increase the Risk of Respiratory Arrest in Patients Requiring Intravenous Midazolam for Procedural SedationJason Arsanious, Angela Rowland, Michael J Sorich, et al.
Cancers|October 18, 2018
Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical TrialsAshley M Hopkins, Anh-Minh Nguyen, Christos S Karapetis, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2010
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial dataM J Sorich, A Vitry, M B Ward, et al.
Pharmaceutical Research|February 26, 2017
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Mafalda M Dias, Michael J Sorich, Andrew Rowland, et al.
Journal of Oncology|July 5, 2021
Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse EventsJessica M Logan, Doug A Brooks, Andrew Rowland, et al.
International Journal of Cancer|June 4, 2020
Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapyAshley M Hopkins, Jordan Wagner, Ganessan Kichenadasse, et al.
European Journal of Clinical Pharmacology|March 25, 2018
Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestriesMadelé van Dyk, Jean-Claude Marshall, Michael J Sorich, et al.
American Journal of Pharmaceutical Education|February 9, 2011
Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy educationDavid M Plevin, Helena M Ward, Michael B Ward, et al.
Biomedicines|January 21, 2022
Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver DiseaseLauren A Newman, Zivile Useckaite, Jillian Johnson, et al.
Pageof 22